List of Ultravate drug patents
Ultravate is owned by Sun Pharm Industries.
Ultravate contains Halobetasol Propionate.
Ultravate has a total of 1 drug patent out of which 0 drug patents have expired.
Ultravate was authorised for market use on 06 November, 2015.
Ultravate is available in lotion;topical dosage forms.
Ultravate can be used as use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis.
The generics of Ultravate are possible to be released after 19 June, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962028 | SUN PHARM INDUSTRIES | Topical steroid composition and method |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Aug 31, 2023 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2015
Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis
Dosage: LOTION;TOPICAL
ULTRAVATE family patents
5
United States
1
New Zealand
1
Korea, Republic of
1
China
1
Hong Kong
1
Philippines
1
Malaysia
1
Brazil
1
South Africa
1
Canada
1
Ukraine
1
Singapore
1
India
1
EA
1
Mexico
1
Japan
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic